Purple Biotech (PPBT) Cash & Equivalents (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Cash & Equivalents data on file, last reported at $5.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $5.6 million, down 3.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (down 3.55% YoY), and the FY2025 annual result was $7.4 million, changed 0.0% from the prior year.
• Cash & Equivalents slipped to $5.6 million in Q1 2026 per PPBT's latest filing, from $8.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $23.5 million in Q1 2022 and troughed at $5.4 million in Q3 2024.
• A 5-year average of $11.9 million and a median of $14.0 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 130.87% in 2022, then sank 64.0% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $15.0 million in 2022, then declined by 3.6% to $14.5 million in 2023, then sank by 48.92% to $7.4 million in 2024, then advanced by 17.78% to $8.7 million in 2025, then slumped by 36.14% to $5.6 million in 2026.
• Business Quant data shows PPBT's Cash & Equivalents at $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $9.6 million in Q3 2025.